Discovery of hippocampal mossy cell involvement to maximize antidepressant effects

May 24, 2019

DGIST faculty clarified that the fundamental neural circuit mechanism involved in antidepressant efficacy to treat depression, one of serious mental diseases in today's society. This is expected to contribute to the development of next antidepressant that can advance the effects and speed of treatment in the future.

DGIST announced on Thurs., May 16th that Professor Yong-Seok Oh's research team at the Department of Brain-Cognitive Science discovered that the activity changes of mossy cells that located in the hippocampus1 which associated with emotion regulation play a crucial role in the treatment efficacy of serotoninergic2 antidepressant.

Depression is a serious mental disease that can not only devastates the quality of the life of patients and families but can also even lead to suicide in an extreme case. South Korea has had the highest suicide rates among OECD countries (24.3 people per population of 100,000 as of 2017) and a total of 566.4 billion KRW has been spent on medical fees, showing that depression is becoming a socioeconomically serious problem.

Although serotonin antidepressant (SSRI3 and SNRI4) are most widely prescribed to treat depression, they have limitations such as high drug-resistance, various side-effects, and treatment effect delays. Serotonin increases immediately within 1 hour after the antidepressant is administered, but treatment effects such as patients' emotional improvement appear after 2-3 weeks at the fastest and takes more than 2 months on average. Such delay in treatment effects has indicated that serotonin does not only determine the efficacy but also shows efficacy by inducing long-lasting neuronal plastic changes in emotional control neural circuit. Yet, such mechanism has not been elucidated so far.
-end-
1 Hippocampus is located under the cerebral cortex in the allocortex and in primates it is in the medial temporal lobe. It is responsible for learning, long-term memory and space concept, cognition, and emotional behavioral control.

2 Serotonin is contained in brain, internal organs, thrombocyte, and mastocyte and exists in the central nervous system of humans and animals to control happiness. It is the primary target of antidepressant.

3 SSRI (Selective Serotonin Reuptake Inhibitors) selectively inhibits the reuptake of serotonin, a neurotransmitter that has antidepressant effect, by increasing serotonin, and is also used in treating anxiety disorder and panic disorder.

4 SNRI (Serotonin-noradrenaline Reuptake Inhibitor is an antidepressant that inhibits the reuptake of serotonin and noradrenalin, the neurotransmitter inside brain.

DGIST (Daegu Gyeongbuk Institute of Science and Technology)

Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.